|
186 Companies |
|
243 Products |
|
243 Products |
|
92 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...1213141516171819202122...5253» |
- volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial completion, Combination therapy: Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Oct 1, 2015
P1, N=5, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- Trial completion, Surgery: PROCERV: Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level (clinicaltrials.gov) - Oct 1, 2015
P4, N=200, Completed, Sponsor: Centre Hospitalier Universitaire de Nice
Active, not recruiting --> Completed Recruiting --> Completed
- Vonjo (pacritinib) / CTI BioPharma
New trial, Combination therapy: Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Sep 30, 2015
P0, N=24, Not yet recruiting, Sponsor: Washington University School of Medicine
- sirolimus / Generic mfg.
Enrollment open, Enrollment change, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Sep 29, 2015
P2, N=510, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Suspended --> Recruiting | N=352 --> 510
- Zyflo (zileuton) / Chiesi
Trial primary completion date, Combination therapy: Evaluating the Safety of Zileuton (Zyflo (clinicaltrials.gov) - Sep 24, 2015
P1, N=18, Recruiting, Sponsor: University of Massachusetts, Worcester
Suspended --> Recruiting | N=352 --> 510 Trial primary completion date: Aug 2015 --> Aug 2016
- Trial primary completion date, Surgery: Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=15, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- dasatinib / Generic mfg.
Trial primary completion date: NordCML007: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (clinicaltrials.gov) - Sep 24, 2015
P2, N=35, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Sep 2018 --> Jun 2016
- luminespib (AUY922) / Ligand
Trial primary completion date: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Sep 24, 2015
P2, N=7, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Sep 2018 --> Jun 2016 Trial primary completion date: Aug 2015 --> May 2015
- busulfan / Generic mfg., clofarabine / Generic mfg.
Trial primary completion date: Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Sep 24, 2015
P2, N=34, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Aug 2015 --> May 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- | Ovastat (treosulfan) / Medac, Medexus
Trial completion, Trial primary completion date: Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT (clinicaltrials.gov) - Sep 16, 2015
P2, N=40, Completed, Sponsor: Center for International Blood and Marrow Transplant Research
Trial primary completion date: Aug 2015 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2015
- Trial completion, Trial primary completion date: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) (clinicaltrials.gov) - Sep 16, 2015
P1/2, N=15, Completed, Sponsor: University Hospital, Basel, Switzerland
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Mar 2011
- dasatinib / Generic mfg.
Trial completion, Enrollment change: CMR-CML: A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (clinicaltrials.gov) - Sep 16, 2015
P2, N=21, Completed, Sponsor: Kanto CML Study Group
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Mar 2011 Not yet recruiting --> Completed | N=30 --> 21
- imatinib / Generic mfg., dasatinib / Generic mfg.
Trial completion, Trial primary completion date: A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia (clinicaltrials.gov) - Sep 16, 2015
P2, N=65, Completed, Sponsor: Kanto CML Study Group
Not yet recruiting --> Completed | N=30 --> 21 Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Jun 2012
- CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
New P1/2 trial: A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (clinicaltrials.gov) - Sep 16, 2015
P1/2, N=30, Recruiting, Sponsor: Cell Therapy Catapult
- dasatinib / Generic mfg.
Enrollment closed: NordCML007: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia (clinicaltrials.gov) - Sep 14, 2015
P2, N=35, Active, not recruiting, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Jun 2012 Recruiting --> Active, not recruiting
- ||| dasatinib / Generic mfg.
New trial, Pleural effusion: PASS: Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (clinicaltrials.gov) - Sep 14, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- Trial primary completion date: Familial Myeloproliferative Disorders (clinicaltrials.gov) - Sep 11, 2015
P=N/A, N=200, Recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2012 --> Jun 2016
- Trial completion: Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases (clinicaltrials.gov) - Sep 10, 2015
P=N/A, N=43, Completed, Sponsor: Medical University of Graz
Trial primary completion date: Dec 2012 --> Jun 2016 Recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion, Enrollment change: Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia (clinicaltrials.gov) - Sep 9, 2015
P=N/A, N=16, Completed, Sponsor: Medical University of Graz
Recruiting --> Completed Recruiting --> Completed | N=20 --> 16
- lenalidomide / Generic mfg.
Trial primary completion date: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Sep 5, 2015
P2, N=48, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | N=20 --> 16 Trial primary completion date: Sep 2015 --> Dec 2015
- || pinometostat (EPZ-5676) / Ipsen
Enrollment closed, Trial primary completion date, Metastases: A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving (clinicaltrials.gov) - Sep 4, 2015
P1, N=60, Active, not recruiting, Sponsor: Epizyme, Inc.
Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Nov 2015
- Campath (alemtuzumab) / Sanofi
Trial completion, Trial primary completion date: T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Sep 4, 2015
P2, N=204, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Nov 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy (clinicaltrials.gov) - Sep 4, 2015
P2, N=28, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed | N=55 --> 28 | Trial primary completion date: Mar 2016 --> Sep 2015
- Enrollment change, Trial termination, Trial primary completion date: Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot (clinicaltrials.gov) - Sep 3, 2015
P=N/A, N=9, Terminated, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed | N=55 --> 28 | Trial primary completion date: Mar 2016 --> Sep 2015 N=60 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jun 2015; Poor recruitment
- lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date, Monotherapy: The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality (clinicaltrials.gov) - Sep 3, 2015
P2, N=36, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
N=60 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Jun 2015; Poor recruitment Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2009 --> Dec 2015
- adavosertib (AZD1775) / AstraZeneca, Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment open, Trial primary completion date, Combination therapy: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 1, 2015
P1, N=24, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2009 --> Dec 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Sep 1, 2015
P=N/A, N=5, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2016 --> Oct 2016 Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014
- Enrollment change, Trial termination, Trial primary completion date, Metastases: A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies (clinicaltrials.gov) - Aug 31, 2015
P1, N=1, Terminated, Sponsor: Indiana University School of Medicine
Recruiting --> Completed | N=20 --> 5 | Trial primary completion date: Dec 2015 --> Nov 2014 N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Apr 2010; Slow accrual
- decitabine / Generic mfg.
Trial primary completion date: Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 27, 2015
P2, N=546, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Apr 2010; Slow accrual Trial primary completion date: Jan 2013 --> Jan 2011
- lenalidomide / Generic mfg.
Enrollment closed: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Aug 26, 2015
P2, N=48, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jan 2013 --> Jan 2011 Recruiting --> Active, not recruiting
- Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
Trial primary completion date, Epigenetic controller: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) - Aug 25, 2015
P1/2, N=58, Recruiting, Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Dec 2015
- Trial withdrawal: Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia (clinicaltrials.gov) - Aug 25, 2015
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Aug 2015 --> Dec 2015 Terminated --> Withdrawn
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 24, 2015
P2, N=210, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Terminated --> Withdrawn Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Unrelated HSCT in Patients With Fanconi Anemia (clinicaltrials.gov) - Aug 21, 2015
P=N/A, N=5, Enrolling by invitation, Sponsor: Neena Kapoor, M.D.
Active, not recruiting --> Completed | N=100 --> 210 | Trial primary completion date: Dec 2015 --> Jan 2015 Trial primary completion date: Mar 2015 --> Mar 2017
- XL019 / Exelixis
Enrollment change, Trial primary completion date: A Phase 1 Study of XL019 in Adults With Polycythemia Vera (clinicaltrials.gov) - Aug 21, 2015
P1, N=3, Terminated, Sponsor: Exelixis
Trial primary completion date: Mar 2015 --> Mar 2017 N=100 --> 3 | Trial primary completion date: Dec 2009 --> Feb 2009
- XL228 / Exelixis
Enrollment change, Trial primary completion date: Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (clinicaltrials.gov) - Aug 21, 2015
P1, N=49, Terminated, Sponsor: Exelixis
N=100 --> 3 | Trial primary completion date: Dec 2009 --> Feb 2009 N=100 --> 49 | Trial primary completion date: Jun 2011 --> Dec 2010
- sirolimus / Generic mfg.
Enrollment change, Trial suspension, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Aug 21, 2015
P2, N=336, Suspended, Sponsor: National Cancer Institute (NCI)
N=100 --> 49 | Trial primary completion date: Jun 2011 --> Dec 2010 N=510 --> 336 | Recruiting --> Suspended
- | Vonjo (pacritinib) / SOBI
Trial initiation date, Trial primary completion date: Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Aug 21, 2015
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
N=510 --> 336 | Recruiting --> Suspended Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Aug 2020 --> Nov 2020
- Trial termination: Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 20, 2015
P1, N=13, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Aug 2020 --> Nov 2020 Active, not recruiting --> Terminated; Inadequate accrual rate
- |||| Bosulif (bosutinib) / Pfizer
Trial completion: B1871006: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias (clinicaltrials.gov) - Aug 20, 2015
P1/2, N=571, Completed, Sponsor: Pfizer
Active, not recruiting --> Terminated; Inadequate accrual rate Active, not recruiting --> Completed
- ||||||| Leukine (sargramostim) / Partner Therap, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion, Phase classification, Trial primary completion date, Combination therapy: High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) (clinicaltrials.gov) - Aug 20, 2015
P3, N=94, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Phase classification: PN/A --> P3 | Trial primary completion date: Nov 2016 --> Aug 2015
- Jakafi (ruxolitinib) / Incyte
New P1 trial: Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Aug 19, 2015
P1, N=30, Not yet recruiting, Sponsor: City of Hope Medical Center
- volasertib (NBL-001) / Oncoheroes, Notable Labs
New P1 trial: VIAC: A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 18, 2015
P1, N=30, Not yet recruiting, Sponsor: University of Alberta
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) (clinicaltrials.gov) - Aug 17, 2015
P2, N=57, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Phase classification: PN/A --> P3 | Trial primary completion date: Nov 2016 --> Aug 2015 Active, not recruiting --> Completed
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 17, 2015
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date, IO biomarker: Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation (clinicaltrials.gov) - Aug 17, 2015
P2, N=15, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: May 2015 --> May 2016
- hydrocortisone / Generic mfg., cytarabine / Generic mfg.
Trial suspension: Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients (clinicaltrials.gov) - Aug 14, 2015
P2, N=38, Suspended, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Suspended
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial suspension: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Aug 14, 2015
P1, N=22, Suspended, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Suspended Recruiting --> Suspended
- ||| Besremi (ropeginterferon alfa-2b) / PharmaEssentia, AOP Orphan Pharma
New P3 trial: PEN-PV: Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (clinicaltrials.gov) - Aug 14, 2015
P3, N=30, Recruiting, Sponsor: AOP Orphan Pharmaceuticals AG
- methoxyamine (TRC102) / Tracon Pharma
Trial completion: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 14, 2015
P1, N=20, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Suspended Active, not recruiting --> Completed